AstraZeneca PLC said Wednesday it has withdrawn applications for regulatory approval for its lung cancer drug Zactima following disappointing trial results.
The pharmaceutical company had been seeking regulatory clearance in the United States and European Union to use Zactima _ generic name vandetanib _ in combination with chemotherapy for treating advanced non-small cell lung cancer.
"The decision to withdraw these submissions was based on an updated analysis that demonstrated no overall survival advantage when vandetanib was added to chemotherapy," the company said. Regulators had also hinted that the results were insufficient for approval, the company added.
AstraZeneca said it will complete a trial program which is expected to give more results on the efficacy of the drug in difference clinical settings.
AstraZeneca shares were down 1 percent at 2,800 pence on the London Stock Exchange.